Obiettivo The SME-based SADEL consortium intends to develop the first generation of oral bio-therapeutics tackling disease targets in the digestive tract, by making optimal use of the Nanofitin (Nf) protein scaffold. Nf based drugs will progress through routes not travelled by antibodies while interacting with targets not modulated by chemical compounds.Existing Nf hits against validated targets will progress to the preparation of Phase I Clinical trials in Ulcerative Colitis (UC). To achieve this, SADEL assembles a virtual biopharmaceutical company with SMEs (70%), academics, clinicians and pharma industry with all cutting-edge skills: production (including GMP), analytics, formulation, preclinical and clinical development, up to licensing.Nfs are small (optimal tissue penetration), exhibit strong resistance to pH and human intestinal fluids (long half-life in digestive track) and their high affinity implies low effective concentration. They also demonstrate strong potential for optimizing pharmacological properties, including reducing immunogenicity.The Nf based drugs will be administered orally, reducing the systemic exposure and avoiding the safety issues reported with systemic administration of antibodies. This requires large quantities of proteins for frequent administration. Nfs are produced in bacterial systems for which GMP-compliant processes are broadly adopted in the industry, with a low cost of goods. The resulting proteins will be formulated for optimal release at the sites of action.The project is designed to address unmet technical challenges while avoiding external risks beyond those related to the scaffold behaviour itself. All additional elements are chosen for documented validation, from targets to evaluation protocols.Achieving SADEL aims will solve unmet patient needs by providing affordable, safe, efficient products in a format raising comfort and compliance to treatment. It will also assess the therapeutic potential of the Nanofitin platform. Campo scientifico medical and health sciencesclinical medicinegastroenterologyinflammatory bowel diseasenatural sciencesbiological sciencesbiochemistrybiomoleculesproteins Programma(i) FP7-HEALTH - Specific Programme "Cooperation": Health Argomento(i) HEALTH.2011.1.4-3 - Development and production of new, high-affinity protein scaffolds for therapeutic use Invito a presentare proposte FP7-HEALTH-2011-two-stage Vedi altri progetti per questo bando Meccanismo di finanziamento CP-FP - Small or medium-scale focused research project Coordinatore INNOVHUB - STAZIONI SPERIMENTALI PER L'INDUSTRIA SRL Contributo UE € 283 613,00 Indirizzo VIA MERAVIGLI 9 B 20123 Milano Italia Mostra sulla mappa Regione Nord-Ovest Lombardia Milano Tipo di attività Research Organisations Contatto amministrativo Ilaria Bonetti (Ms.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato Partecipanti (9) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto ELAN PHARMA INTERNATIONAL LIMITED Partecipazione conclusa Irlanda Contributo UE Nessun dato Indirizzo TREASURY BUILDING, LOWER GRAND CANAL STREET DUBLIN 2 Mostra sulla mappa Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo William Daniel (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato AFFILOGIC Francia Contributo UE € 995 951,74 Indirizzo 24 RUE DE LA RAINIERE PARC CLUB DU PERRAY 44300 Nantes Mostra sulla mappa Regione Pays de la Loire Pays de la Loire Loire-Atlantique Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Olivier Kitten (Mr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato EREVNITIKO KENTRO VIOIATRIKON EPISTIMON ALEXANDROS FLEMINGK Grecia Contributo UE € 292 320,00 Indirizzo FLEMING STREET 34 16672 Vari-Athens Mostra sulla mappa Regione Αττική Aττική Ανατολική Αττική Tipo di attività Research Organisations Contatto amministrativo George Kollias (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato INTESTINAL BIOTECH DEVELOPMENT Francia Contributo UE € 1 055 016,26 Indirizzo BOULEVARD DU PROF JULES LECLERCQ, FACULTE DE MEDECINE POLE RECHERCHE AMPHI J&K 59045 LILLE Mostra sulla mappa Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Nghiep Truong Tan (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato EUROPEAN CROHN'S AND COLITIS ORGANISATION Austria Contributo UE € 74 896,00 Indirizzo UNGARGASSE 6/13 1030 WIEN Mostra sulla mappa Tipo di attività Research Organisations Contatto amministrativo Nicole Eichinger (Mrs.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato UNIVERSITE DE GENEVE Svizzera Contributo UE € 723 544,00 Indirizzo RUE DU GENERAL DUFOUR 24 1211 Geneve Mostra sulla mappa Regione Schweiz/Suisse/Svizzera Région lémanique Genève Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Leonardo Scapozza (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato GENIBET - BIOPHARMACEUTICALS SA Portogallo Contributo UE € 468 796,00 Indirizzo AVENIDA DA REPUBLICA QUINTA DO 2781 901 Oeiras Mostra sulla mappa Regione Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Teresa Alves (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA Portogallo Contributo UE € 921 110,40 Indirizzo AVENIDA DA REPUBLICA QUINTA DO MARQUES 2781-901 Oeiras Mostra sulla mappa Regione Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa Tipo di attività Research Organisations Contatto amministrativo Manuel Carrondo (Prof.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato FERRING PHARMACEUTICALS AS Danimarca Contributo UE € 136 545,00 Indirizzo KAY FISKERS PLADS 11 2300 KOBENHAVN Mostra sulla mappa Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Gregoire Schwach (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato
